Lista de obras -

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

artículo científico publicado en 2020

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

artículo científico publicado en 2019

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

artículo científico publicado en 2018

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

artículo científico publicado en 2017

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2017

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

artículo científico publicado en 2018

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

artículo científico publicado en 2017

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

artículo científico publicado en 2014

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2017

Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation

artículo científico

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

artículo científico publicado en 2018

Advances in patient care through increasingly individualized therapy

artículo científico publicado en 2019

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

artículo científico publicado en 2018

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

artículo científico publicado en 2016

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

artículo científico publicado en 2015

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation

artículo científico publicado en 2017

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

scientific article published on 27 September 2016

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

artículo científico publicado en 2017

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

scientific article published on 04 May 2020

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

artículo científico publicado en 2015

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

scientific article published on 13 August 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

artículo científico publicado en 2018

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

artículo científico publicado en 2017

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

artículo científico publicado en 2017

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

artículo científico publicado en 2020

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

artículo científico

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

scientific article published on 29 October 2020

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

artículo científico publicado en 2014

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

artículo científico publicado en 2017

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2016

Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1

scientific article published on 01 April 2020

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

artículo científico publicado en 2015

Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations

scientific article published on 17 August 2020

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

artículo científico publicado en 2020

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

artículo científico publicado en 2015

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

scientific article published on 01 December 2018

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease

scientific article published on 07 May 2019

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

artículo científico publicado en 2015

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

artículo científico publicado en 2016

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

artículo científico publicado en 2016

Early detection of transformation to BPDCN in a patient with MDS

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

artículo científico publicado en 2016

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

artículo científico publicado en 2018

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

scientific article published on 09 April 2019

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

artículo científico publicado en 2016

Hematopoiesis under telomere attrition at the single-cell resolution

artículo científico publicado en 2021

How I treat acute myeloid leukemia in the era of new drugs

artículo científico publicado en 2020

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

artículo científico publicado en 2020

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

artículo científico publicado en 2019

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

scientific article published on 30 April 2020

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2017

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

artículo científico publicado en 2014

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

scientific article published on 04 May 2020

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels

scientific article published on 06 April 2018

Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax

artículo científico publicado en 2020

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2018

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

artículo científico publicado en 2018

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

scientific article published on 29 April 2019

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

artículo científico publicado en 2016

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

scientific article published on 01 February 2020

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

scientific article published on 27 February 2019

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

artículo científico publicado en 2015

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

artículo científico publicado en 2014

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

artículo científico publicado en 2021

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

artículo científico publicado en 2016

Low frequency of H3.3 mutations and upregulated DAXX expression in MDS ⬇️

artículo científico publicado el 9 de mayo de 2013

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

scientific article published on 01 May 2020

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

scientific article published on 01 March 2020

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia

artículo científico publicado en 2017

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

artículo científico publicado en 2020

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable

artículo científico publicado en 2018

New directions for emerging therapies in acute myeloid leukemia: the next chapter

artículo científico publicado en 2020

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

artículo científico publicado en 2018

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

scientific article published on 08 October 2020

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

artículo científico publicado en 2016

Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia

scholarly article by Chi Young Ok et al published February 2019 in Haematologica

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia

scientific article published on 22 January 2019

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

artículo científico publicado en 2020

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

scientific article published on 20 December 2018

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

artículo científico publicado en 2020

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

scientific article published on 03 March 2020

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

artículo científico

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

artículo científico publicado en 2017

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

artículo científico publicado en 2019

Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

artículo científico publicado en 2020

RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype

artículo científico publicado en 2015

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

artículo científico publicado en 2018

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

artículo científico publicado en 2017

SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML

artículo científico publicado en 2018

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

artículo científico publicado en 2017

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

artículo científico publicado en 2020

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

artículo científico publicado en 2018

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia

scientific article published on 16 July 2019

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation

scientific article published on 29 August 2019

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

scholarly article by Warren Fiskus et al published 15 January 2019 in Blood Cancer Journal

Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

artículo científico publicado en 2020

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

artículo científico publicado en 2016

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

scientific article published on 19 June 2020

The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes

artículo científico publicado en 2020

Time to blur the blast boundaries

scientific article published in 2022

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

artículo científico publicado en 2017

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

scientific article published on 10 December 2018

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

scientific article published on 31 May 2019

Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.

artículo científico publicado en 2017

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes

scientific article published on 06 December 2018

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

scholarly article by Courtney D DiNardo et al published 25 October 2018 in Blood

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy

scientific article published on 23 October 2019

Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

scientific article published on 02 December 2020

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study

artículo científico publicado en 2020

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2017

Lista de obras de

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

Advances in patient care through increasingly individualized therapy

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

Early detection of transformation to BPDCN in a patient with MDS

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

Hematopoiesis under telomere attrition at the single-cell resolution

How I treat acute myeloid leukemia in the era of new drugs

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels

Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

Low frequency of H3.3 mutations and upregulated DAXX expression in MDS ⬇️

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia